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Background: Gefitinib is active in patients with pretreated non-small-cell lung cancer (NSCLC). We evaluated the
activity and toxicity of gefitinib first-line treatment in advanced NSCLC followed by chemotherapy at disease
progression.
Patients and methods: In all, 63 patients with chemotherapy-naive stage IIIB/IV NSCLC received gefitinib 250 mg/
day. At disease progression, gefitinib was replaced by cisplatin 80 mg/m2 on day 1 and gemcitabine 1250 mg/m2 on
days 1, 8 for up to six 3-week cycles. Primary end point was the disease stabilization rate (DSR) after 12 weeks of
gefitinib.
Results: After 12 weeks of gefitinib, the DSR was 24% and the response rate (RR) was 8%. Median time to
progression (TtP) was 2.5 months and median overall survival (OS) 11.5 months. Never smokers (n = 9) had a DSR of
56% and a median OS of 20.2 months; patients with epidermal growth factor receptor (EGFR) mutation (n = 4) had
a DSR of 75% and the median OS was not reached after the follow-up of 21.6 months. In all, 41 patients received
chemotherapy with an overall RR of 34%, DSR of 71% and median TtP of 6.7 months.
Conclusions: First-line gefitinib monotherapy led to a DSR of 24% at 12 weeks in an unselected patients population.
Never smokers and patients with EGFR mutations tend to have a better outcome; hence, further trials in selected
patients are warranted.
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introduction
Lung cancer is a leading cause of cancer mortality and cases
are expected to increase worldwide. Over 85% of lung cancer
patients present with non-small-cell lung cancer (NSCLC),
the majority with unresectable disease. Since the 1990s,
platinum-based combination chemotherapy is the standard
first-line treatment in advanced NSCLC patients with good
performance status (PS) [1]. Despite some improvements,
efficacy and tolerability of chemotherapy remain unsatisfactory.
Response rates (RRs) to standard chemotherapy regimens are
in the 20% range; about one-third of patients survive for >1
year. Platinum-based chemotherapy is associated with
moderate to severe hematological and non-hematological
toxic effects in a majority of patients [2].
Gefitinib is an oral, epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). As second-line
therapy, gefitinib produced RRs comparable to those
previously reported for second-line chemotherapy [3, 4].
Main toxic effects reported in a recent phase III study were
rash and diarrhea in 37% and 27%, respectively (any grade;
grade III/IV 1.6% and 2.8%) [5]. Patients with
adenocarcinoma, females and patients of Asian origin as well
as never smokers respond particularly well. Erlotinib,
a similar EGFR-TKI has been approved as second- and
third-line therapy for NSCLC on the basis of improved
survival when compared with placebo [6]. In a similar trial
with gefitinib, however, a survival benefit was shown only in
patients of Asian origin and in never smokers [5].
In 2004, two landmarks studies [7, 8] reported a correlation
between response to gefitinib and EGFR gene mutations
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the TK domains (exons 18–21) in patient’s tumors. Further
reports correlated response to EGFR-TKI’s with high EGFR
gene copy number (FISH analysis), and showed resistance in
patients whose tumors harbored KRAS mutations [9, 10].
In this multicenter phase II trial, we assessed the efficacy and
tolerability of gefitinib as first-line treatment in unselected
patients with advanced NSCLC, followed by standard
chemotherapy at disease progression. The primary end point
was the disease stabilization rate after 12 weeks of gefitinib
(DSR 12). Association of response with molecular markers was
examined and longitudinal quality-of-life (QoL) patterns were
assessed.
patients and methods
eligibility criteria
Patients with histologically or cytologically confirmed, chemotherapy-
naive, inoperable stage IIIB/IV NSCLC and measurable disease (Response
Evaluation Criteria in Solid Tumors criteria [11]) were eligible. Eligibility
criteria included age >18 years, PS World Health Organization (WHO) of
zero to one, adequate bone marrow function, normal kidney function and
adequate liver function. Patients could only be included if the local
investigator felt it to be clinically safe to withhold standard chemotherapy
for 6 weeks. Patients with symptomatic and/or untreated brain metastases
and patients with evidence of active interstitial lung disease were excluded.
Not allowed was the use of phenytoin, carbamazepine, rifampicin,
barbiturates or St Johns Wort. The study was conducted according to the
guidelines of Good Clinical Practice [13], the Helsinki Declaration [12] and
Swiss regulatory authorities requirements [14, 15] and was approved by the
ethic committees of all participating institutions.
treatment
Gefitinib 250 mg/day p.o. was given until documented disease progression,
unacceptable toxicity or patient’s refusal. After disease progression,
chemotherapy was initiated with gemcitabine 1250 mg/m2 (30 min) on
days 1, 8 and cisplatin 80 mg/m2 (60 min) on day 1, repeated every 3 weeks
for up to six cycles. Chemotherapy was stopped early in the case of disease
progression, unacceptable toxicity or patient’s refusal. Steroids and
5-hydroxytryptamine-3 antagonists were recommended for antiemetic
prophylaxis. Prophylactic granulocyte colony-stimulating factor or
erythropoietin was given only after febrile neutropenia or anemia. In case of
peripheral neuropathy, hearing impairment or renal insufficiency, cisplatin
was replaced by carboplatin area under the curve 5 (30 min). Standard dose
modifications for toxicity were foreseen.
assessments
Baseline assessments included medical history and smoking habits,
computed tomography (CT) scan of thorax/abdomen, bone scan and
magnetic resonance imaging (or CT) of the brain (in case of neurologic
symptoms). During gefitinib treatment, a physical examination and
hematologic and biochemical testing were done at baseline and every
3 weeks until week 12, then every 6 weeks. QoL questionnaires were
completed at week 0, 3, 6, 12, 18 and every 12 weeks thereafter. CT scans
were repeated at week 6, 12, 18 and every 12 weeks thereafter. Before
chemotherapy, new baseline assessments including QoL were obtained.
During chemotherapy, hematological values were measured weekly and
blood chemistry at each cycle. QoL questionnaires were completed at day 1
of cycle 3 and 5. CT scans were repeated after cycle 2, 4 and 6. During
follow-up, physical examination, blood tests, QoL questionnaires and CT
scans were scheduled every 12 weeks. After disease progression (RECIST
criteria [11]), survival status was assessed every three months.
Adverse events (AEs) were assessed at each patient contact and
reported according to National Cancer Institute—Common Terminology
Criteria version 3. Relation to trial treatment was graded in five categories
and listed as toxicity if at least possibly related to trial treatment.
For all patients responding or with stable disease (SD) after 6 or
12 weeks, CT scans were centrally reviewed by a panel of independent
radiologists.
statistical considerations
The primary end point was DSR12 under gefitinib. Secondary end points
included objective response, time to progression (TtP), QoL and AEs
under either treatment, DSR under chemotherapy and overall survival
(OS).
The sample size was estimated using Simon’s two-stage optimal design
[16] for a 5% type 1 error probability, 90% power, promising and
unpromising DSR12 of 50% and 30%, respectively. As accrual was
expected to be fast, the stage 1 stopping rule was modified by Herndon’s
approach [17]. The stage 1 analysis was carried out on the basis of data
of 24 patients and indicated continuation of the trial. Gefitinib would be
considered promising for further investigations if at least 26 of 63 patients
reach disease stabilization (DS) at 12 weeks.
Univariate associations between DS12 and binary covariables were
investigated by two-sided Fisher’s exact tests. The combined influence of
these covariables on DS12 was investigated by a multiple logistic regression.
The survival functions and medians of TtP and OS were estimated by
Kaplan–Meier’s method. OS between strata defined by selected
covariables were compared by log-rank tests. The joint association
between these covariables and OS was investigated by Cox regression.
All tests were of exploratory nature without adjustment for multiple
testing. Data analysis were carried out using SAS 9 (SAS Institute Inc., Cary,
NC. und Insightful Corp., Seattle, Washington, USA.)
translational research
Specimens were reviewed (LB) and classified according to WHO criteria
[18]. Molecular analysis was carried out on unstained tissue sections (4 lm)
or Papanicolaou-stained cytological specimens.
Laser microdissection and DNA sequence analysis: at least 80 tumor
cells were captured by a laser microdissection system [19] in a tube
containing 80 mcl 1· PCR buffer. In all, 20 ll proteinase K was added
and incubated overnight at 56C. PCR conditions were activating of the
Taq polymerase 95C for 11 min, 50 cycles of 95C for 20 s, 59C for 10 s,
72C for 50 s, followed by 4 min at 72C. In all, 0.5 ll of the product of
the first PCR was used for the second semi-nested multiplex PCR.
Primers (not shown) were digested in a PTC-100 thermocycler
(BioConcept, Allschwil, Switzerland). Sequencing PCR was carried out
using the BigDye Terminator v1.1 kit (Applied Biosystems, Rotkreuz,
Switzerland).
Experimental condition of the 80 cycles of linear amplification is as
follows: denaturation 10 min at 95C; annealing 10 s at 55C and
elongation 4 min at 60C. Flowable polymers were used to dynamically
coat capillaries. Split argon laser beam allows simultaneous illumination
of the 16 capillaries from both sides at the detection cell. Fluorescence
signal emitted from the DNA fragments were collected on Charge-coupled
device (CCD) camera and visualized using the sequencing analysis software
5.2 (Applied Biosystems).
FISH analysis
Locations of carcinoma cells were saved by a relocation software
(Mark&Find Module, Carl Zeiss Vision GmbH, Halbermoos, Germany)
and an automated stage (Type 00-24-473-0000, Carl Zeiss AG, Oberkochen,
Germany) before hybridization.
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LSI EGFR SpectrumOrange/CEP7 SpectrumGreen dual color probe
set (Abbott/Vysis, Downers Grove, Illinois, USA) was used. FISH was
carried out as previously described [20, 21]. The mean number of scored
cells was 96 (612 cells, range 50–100) in histological specimens and 66.4
(637.6 cells, range 11–100) in cytological specimens.
quality of life
QoL and disease-related symptoms were assessed by the Functional
Assessment of Cancer Therapy-Lung (FACT-L) scale [22, 23]. The
self-reported questionnaire comprises four general subscales (physical,
functional, social and emotional well-being) and one lung cancer
symptom-specific subscale (LCS). The trial outcome index (TOI) is
derived by adding scores of the physical well-being and the functional
well-being subscales and the LCS.
Questions are answered on a five-point scale ranging from ‘not at all’
(0) to ‘very much’ (4). Maximum scores are 28 for LCS, 84 for TOI and
136 for FACT-L, respectively. Higher scores indicate better QoL or fewer
symptoms [24]. For each time point and QoL score, the median value of the
difference from baseline was evaluated. Due to decreasing number of
patients over time the analysis remains descriptive. Only QoL forms
completed at the scheduled visits or up to 7 days before were included into
the analysis. For patients with NSCLC, a difference of 2–3 points in LCS
score and a difference of 5–7 points in TOI are considered as clinically
relevant [25].
results
From November 2003 to October 2004, 63 patients were
included. Patient characteristics are summarized in Table 1.
response
gefitinib. All 63 patients started gefitinib treatment and were
assessable. Median treatment duration was 2.5 (0.1–21.2)
months. Investigator reported objective responses at week
12 were 1 complete remission (CR), 5 partial remissions (PRs)
and 18 SDs, resulting in an objective RR of 9.5% and a DSR12
of 38% [exact 95% confidence interval (CI) 26.2% to 51.2%].
Independent radiological review was carried out in 26 cases
having shown a stabilization of disease according to local
investigators. Investigator’s assessments were confirmed in
16 and could not confirm DS in 8 and PR in 1, and in 1 patient
CR was changed to PR. With reviewed results, 15 patients
reached DS with DSR12 of 24% (exact 95% CI 12.9% to
38.8%). Table 2 shows response data for all 63 patients with
reviewed results where applicable. Reason for stopping
gefitinib was progression in 49 patients, clinical
deterioration in 4, death in 8 (7 due to tumor and 1 lung
embolism) and nonfatal serious AE in 1 (perforated
appendicitis). One patient was still on gefitinib at the time
of analysis.
DS12 was associated with smoking status [P = 0.031, odds
ratio (OR) = 0.186] and EGFR mutation status (P = 0.037,
OR = 12.3). A multiple logistic regression model confirmed
the association between EGFR mutation status and DS12
(Table 3). There was no significant association between DS12
and the other factors investigated.
chemotherapy. In all, 41 patients started chemotherapy.
Reasons for not receiving chemotherapy were death (n = 8),
poor PS (4), refusal (3), investigators decision (2),
irradiation for cerebral metastases (2), serious AE (perforated
appendicitis, 1), chemotherapy in a different hospital (1)
and continuation of gefitinib (1). Totally, 171 cycles were
administered (1–6, median five cycles per patient). In all,
20 patients received six courses. PR was achieved in 14 patients
and SD in 15 patients for an overall RR of 34.1% and a DSR
of 70.7%. Three patients were not assessable (two stopped
therapy for toxicity before first assessment and one not
assessed due to treatment delay).
survival analysis
Median follow-up time of the 15 patients still alive was 21.6
months. OS (Figure 1) and TtP are detailed in Tables 2. Median
TtP under post-gefitinib chemotherapy, calculated from day 1
of chemotherapy, was 6.8 months for the 41 patients with
chemotherapy and 4.8 months for all the 63 patients.
According to the univariate analysis for FISH, KRAS,
EGFR, age (‡/<65 years), gender, PS (0/1), smoking status
(never/smoker), adenocarcinoma, skin toxicity and disease
stage, only patients experiencing any skin toxicity to gefitinib
had significantly different survival (n = 63, P = 0.022); the
corresponding multiple Cox model (without FISH, KRAS
and EGFR) found no statistically significant covariables.
toxicity
In all, 61 patients were assessable. Two patients were not
assessable due to death (tumor/lung embolism) before 4 weeks
of treatment. Grade III toxic effects during gefitinib were one
Table 1. Patient characteristics
n 63
Age
Median 62 years
Range 39–85 years
Gender
Female 24 (38%)
Male 39 (62%)
Stage
IIIB 14 (22%)
IV 49 (78%)
Histology
Adenocarcinoma 27 (43%)
Bronchioloalveolar carcinoma 5 (8%)
Squamous cell carcinoma 13 (21%)
NSCLC NOS 18 (29%)
ECOG performance status
0 36 (57%)
1 27 (43%)
Metastatic sites
Lung 37
Bone 22
Adrenal glands 18
Liver 6
Brain 3
Other (soft tissue, spleen) 3
NSCLC, non-small-cell lung cancer; NOS, not otherwise specified; ECOG,
Eastern Cooperative Oncology Group.
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neutropenia, five elevated Alanine-Aminotransferase, one
elevated creatinine clearance, Aspartate-Aminotransferase
alkaline phosphatase each, one hypoalbuminemia and one
hyponatriemia. Nonlaboratory toxic effects grade III were as
follows— three patients with diarrhea, and one case of each of
the following: dry skin, pruritus, musculoskeletal pain,
abdominal pain, neurological symptoms of the legs, deep vein
thrombosis and dehydration. No grade IV/V toxic effects were
observed and no patient stopped gefitinib due to toxicity. In 36
patients (59%), skin toxicity of any grade was reported; no
interstitial lung disease was seen.
chemotherapy. All 41 patients receiving chemotherapy were
assessable for toxicity. Grade III events: fatigue and infection
in three patients, mucositis, diarrhea, vomiting, cardiac
problems in two patients each, nausea, anorexia, hearing loss,
glaucoma, weakness, confusion, renal failure and
hyperbilirubinemia in one patient each. Grade III/IV
toxicity: neutropenia in 7 of 9 patients, thrombocytopenia
in 13 of 11 patients. Further, one lung embolism and one
Syndrome of Inadequate ADH-Secretion grade IV were
reported.
translational analyses
In all, 57 patients consented for molecular analyses (Table 4).
Four EGFR mutations were detected, two exon 19 deletions
(both patients responding to gefitinib) and two L858R
mutations on exon 21 (one SD and one Progressive Disease to
gefitinib). Clinical and molecular data of these patients are
summarized in Table 5. EGFRmutations were more frequent in
females (2 of 20) than in males (2 of 37) and in never smokers
(2 of 6) than in former or current smokers (2 of 51). All
patients with EGFR mutation were also FISH positive and none
had a KRAS mutation.
From the 34 patients with high EGFR gene copy number
(Cappuzzo-criteria [10]), 5 had true EGFR gene amplification
(none with DS).
Initial FISH analysis was done on cytological material in
20 patients and on histologies in 37. The overall positivity
rate was 59% (cytologies 55% and histologies 62%). A
blinded FISH reanalysis by a second team was carried out in
47 samples (10 samples with bleached fluorescent signals).
Table 2. Response to gefitinib week 10–12 after independent radiological review (all study patients)
n PR SD PD Early death RR % DSR % TtP (months) OS (months)
All patients 63 5 10 43a 5b 7.9 23.8 2.5 11.4
Never smokers 9 4 1 4 0 44.4 55.6 9.4 20.2
Females 24 3 2 17 2 12.5 20.8 2.1 12.0
Adenocarcinoma 32 2 5 21 4 6.3 21.9 1.6 9.4
aIncluding one patient with clinical deterioration only.
bFour early deaths due to tumor without documented PD, one lung embolism.
PR, partial remission; PD, Progressive Disease; SD, stable disease; RR, response rate (intention-to-treat analysis); DSR, disease stabilization rate (intention-to-
treat analysis); TtP, median time to progression (weeks); OS, median overall survival.
Overall Survival (n = 63)
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Median OS = 11.5 months
Figure 1. Kaplan–Meier curves for overall survival.
Table 3. Univariate analysis and multiple logistic regression of reviewed DSs at week 12 of gefitinib
n PR SD PD Early death RR % DSR % TtP (months) OS (months)
All patients 57 3 10 40a 4 5.3 22.8 2.4 11.4
EGFR mutation positive 4 2b 1c 1c 0 50 75 7.5 Not reached
FISH positive 34 3 4 24a 3 8.8 20.5 2.3 11.8
KRAS mutation positive 5 0 0 4 1 0 0 2.4 9.0
aIncluding one patient with clinical deterioration only.
bIn all, 15 bp deletion E746-A750 and 18 bp deletion exon 19.
cBoth L858R exon 21.
PR, partial remission; SD, stable disease; RR, response rate (intention-to-treat analysis); DSR, disease stabilization rate (intention-to-treat analysis); TtP, time
to progression; OS, overall survival; EGFR, epidermal growth factor receptor.
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Rescoring confirmed initial results in all 14 cytology samples,
whereas 7 of the 20 histology specimens initially scored
positive were retested negative.
quality of life
QoL forms submission rate was 100% at start of treatment,
80% at gefitinib week 6 (44 received and analysed/55 expected)
and 84% (27/32) at week 12. At the initiation of chemotherapy,
submission rate was 63% (26/41), and 50% (14/28) and
43% (10/23) at week 6 and 12, respectively. Main reasons
for missing forms were that the questionnaire was not
presented to the patient or not completed at the due time point.
Median QoL scores are shown in Table 6. No associations
between responses to gefitinib and QoL scores were observed.
At week 12 of gefitinib, 29%, 15% and 41% of patients had
relevant improvements of FACT-L, TOI and LCS, respectively,
and 54%, 62% and 33% remained stable (percentage on the
basis of patients with available data). During chemotherapy
at week 12, 43%, 29% and 43% reported improvement and
28%, 43% and 43% stabilization.
discussion
The primary end point of this trial of first-line gefitinib
treatment in advanced NSCLC was DSR12. With 24% of
patients not progressing at 12 weeks, the treatment did not
meet the predefined criteria for further investigation. Although
the study proved first-line gefitinib to be a safe strategy with
OS times comparable to up-front chemotherapy, a potential
benefit of the sequential strategy most probably could only be
Table 4. Reviewed response by molecular analysis (patients consenting for molecular analyses only)
Site Material Histological type EGFR mutation KRAS (exon 2) FISH status
(Cappuzzo et al. [10])
Lymph node Biopsy SqCLC L858R in exon 21 Negative High polysomy
Lung Biopsy AC L858R in exon 21 Negative High polysomy
Lung Biopsy NSCLC NOS 18 bp deletion in exon 19 (L747-S752) Negative High polysomy
Lung Cytology NSCLC NOS 15 bp deletion in exon 19 (E746-A750) Negative High polysomy
AC, Adenocarcinoma; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; NOS, not otherwise specified; SqCLC, Squamous Cell
Carcinoma.
Table 5. Characteristics of EGFR-mutated samples
Gefitinib baseline Gefitinib week 6 Gefitinib week 12 Chemo baseline Chemo week 6 Chemo week 12
FACT-L 96 (53–135) 96 (65–136) 96 (50–136) 87 (61–132) 105 (76–134) 107 (76–135)
n 63 42 24 23 14 10
TOI 62 (31–83) 55 (26–84) 59 (31–84) 49 (28–81) 62 (45–82) 65 (32–83)
n 63 44 27 24 14 10
LCS 21 (10–27) 21 (7–28) 21 (15–28) 17 (10–27) 24 (14–27) 24 (15–27)
n 63 44 27 25 14 10
QoL, quality of life; Chemo, chemotherapy; FACT-L, Functional Assessment of Cancer Therapy-Lung; TOI, trial outcome index; LCS, lung cancer symptom-
specific subscale.
Table 6. Median (range) of QoL scores
Variable n DS No DS P value (univariate) P value (logistic
regression, n = 53)
Age £65/>65 years 63 7/8 29/19 0.3838 0.29
Sex female/male 63 5/10 19/29 0.7665 0.05
Performance status 0/1 63 11/4 25/23 0.232 0.07
Stage IIIB/IV 63 3/12 11/37 1 0.12
Smoking never/ever 62 5/10 4/34 0.0308 0.34
Other histologies/adenocarcinoma 63 8/7 23/25 0.7735 0.69
Skin toxicity no/yes 63 4/11 23/25 0.232 0.61
FISH negative/positive 54 5/7 15/27 0.7435 0.36
KRAS wild type/mutation 55 12/0 38/5 0.5743 0.41
EGFR wild type/mutation 55 10/3 41/1 0.0373 0.02
DS, disease stabilization; EGFR, epidermal growth factor receptor.
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found in selected patient groups. A benefit in these patients
could be an improvement of treatment efficacy or related to
QoL through the avoidance of chemotherapy toxicity.
A trial testing first-line erlotinib in a nonenriched group of
NSCLC patients was presented in 2006 by Giaccone et al. [26].
A nonprogression rate of 53% after 6 weeks of treatment was
reported, identical to our data for the 6-weeks time point.
Jackman et al. [27] in 2007 reported on first-line erlotinib in
elderly patients and found comparable results: 10% PR and
additional 41% SD after 2 months. These as well as our
results indicate that TKI’s have comparable activity in first-line
use as in pretreated patients. Further, first-line TKI trials
were reported by Asian authors, partially with frequent
occurrence of interstitial lung disease [28]. Lee et al. [29]
reported on a phase II study in Asian never-smoking patients
with adenocarcinoma and found impressive results with 69%
PR and additional 11% SD.
We have seen best outcomes in response as well as
survival times in never smokers and in EGFR mutation
carriers (exon 19 deletion or exon 21 L858R point mutation).
Among the four, EGFR-mutated tumors response was restricted
to those with exon 19 deletions. This lends support to previous
evidence indicating that exon 19 deletion is the most predictive
EGFR mutation type [30]. As previously shown, KRAS
mutations are mediators or indicators of resistance to gefitinib
[31].
In contrast to earlier publications, FISH analysis of EGFR
copy number (true amplifications and ‘high polysomy’
according to Cappuzzo criteria [10]) did not correlate with
clinical outcomes. This discrepancy could be due to the small
number of patients in this study, but may also be explained
to some degree by interobserver variation in FISH scoring.
In fact, reanalyses of the histology specimens by a second team
showed low reproducibility of the results. There is a need to
quantify the problem of inter- and intraobserver variabilitiy
in the detection of high polysomy of the EGFR gene in
appropriately sized patient series, as such data do not yet
exist in the literature.
According to our results, patients would be best selected
for TKI treatment according to smoking status and to EGFR or
KRAS mutation status. In the univariate analysis, patients
experiencing skin toxicity had significantly longer survival;
this correlation was not uniformly reported in earlier series
and was not confirmed in our multivariate analysis. The
emergence of skin rash may be influenced by the duration of
treatment as well.
Gefitinib was very well tolerated and no patient stopped
gefitinib due to toxicity. QoL levels were maintained during
gefitinib treatment, declined at disease progression and
increased again during chemotherapy. Because only
nonprogressors completed QoL forms during chemotherapy
and the number of evaluable forms was low, analyses remained
descriptive and should be interpreted with caution. QoL
compliance was low due to organizational problems rather than
to patient-related factors.
The primary end point (DSR12) was verified by an
independent radiological review which significantly altered
response results; DSR12 was corrected from 38% as
per investigators’ reports to 24% after review, thus
underscoring the importance of independent evaluations in this
type of trials.
In conclusion, gefitinib first-line therapy did not reach the
predefined efficacy boundaries for further investigation in this
setting. Compared with the results from trials of up-front
chemotherapy, patients pretreated with gefitinib reached
similar survival times. Furthermore, gefitinib showed
comparable efficacy in first-line use as in pretreated patients
and stabilized QoL in nonprogressing patients. First-line use
should further be investigated in patients selected according
to smoking history or mutational status including EGFR and
KRAS and should include QoL analyses.
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